TSS results were 0 and 16, and RADS scores were 0 and 4, respectively

TSS results were 0 and 16, and RADS scores were 0 and 4, respectively. severe complications and did not receive any specific treatment for the two diseases. Acknowledgement of COVID-19 in patients with CLL is usually a challenging task and the most accurate methods are necessary to overcome the diagnostic troubles encountered. Keywords: CLL, CLL contamination, antibodies, molecular diagnosis, virology 1. Case Statement An 84-year-old obese man was diagnosed with CLL in 2006. In 2017, he underwent transcatheter aortic valve implantation (TAVI) because of the worsening of his atrial fibrillation due to aortic stenosis. Bone marrow aspiration, circulation cytometry immunophenotyping and hematological investigations were performed over the course of disease, including a Binet stage C, Rai stage IV and a European Cooperative Oncology Group (ECOG) overall performance score of 1 1. The CLL was treated for several years only with prednisone at 10 mg per day. In February 2020, based on a peak of lymphocytosis and circulation cytometry analysis, treatment with ibrutinib was considered. However, he by no means started such treatment because in March 2020, he became symptomatic with a sore throat, fever (39 C), dyspnea and a dry cough, associated with a paO2 < 80%. For this reason, he was hospitalized in the rigorous care unit. On admission, he showed acute hypoxemic respiratory failure, with a pO2 = 35, and started noninvasive ventilation (NIV) therapy 12-10, with FiO2 55%. High-resolution CT (HRCT) of the lung showed the typical aspect of interstitial pneumonia, with a Rislenemdaz ground glass appearance. The total severity score (TSS) and the COVID RADS were calculated in January 2020, before the onset of the symptoms, and in March 2020 during the acute phase of the disease according to the methods previously explained [1,2]. TSS results were 0 and 16, and RADS scores were 0 and 4, respectively. The HRCT scan also Rislenemdaz showed Rislenemdaz indicators of distal, bilateral lung thromboembolism (Physique 1), and treatment with fondaparinux (Arixtra) at 1.5 mg/day was administered. Based on the results of the HRCT scan and thromboembolic complications, considering the TSS and CO-RADS scores, the occurrence of SARS-CoV-2 contamination was suspected, and nasal/oropharyngeal swabs followed by a real-time reverse-transcription polymerase chain reaction (rRT-PCR) test were performed. We used two different packages, APAF-3 namely the Allplex? 2019-nCoV Assay (Seegene MuDTTM, Seoul, Republic of Korea) and the RNA Detection kit (DAAN Gene Co. LTD, Guangzhou, Guangdong, China). The result was unfavorable with both. In agreement with WHO recommendations in case of suspected cases, we repeated the test many times, with the same unfavorable results (Table 1). Therefore, the patient was not transferred to the isolation ward for appropriate patient management in accordance with the specific COVID-19 Integrated Care Pathway (ICP), recently published [3]. He was admitted first to rigorous care and then the pneumatological unit, where a bronchoalveolar lavage (BAL) was performed without any special protection. Physicians attending to him were therefore potentially exposed to contamination. The BAL specimen was subjected to cytological assessment and Rislenemdaz culture, in search of other possible bacterial and Rislenemdaz fungal infections. On that occasion, another attempt was made to detect the SARS-CoV-2 computer virus in the BAL specimen using the kit by Seegene. The rRT-PCR failed to identify the computer virus, probably because of the delayed timing of the exam. Open in a separate window Physique 1 (A,B) CT scan of the chest showing multiple large bilateral patchy ground-glass opacities (GGOs) and consolidations, mostly including peripheral lung parenchyma. (C,D) CT scan of the chest with iodinated contrast. Red circles: Thromboembolic alterations involving sub-segmentary.